Virus SARS-CoV-2 S protein (944-1214 aa) Monoclonal antibody, PBS Only

SARS-CoV-2 S protein (944-1214 aa) Monoclonal Antibody for WB,Indirect ELISA

Host / Isotype

Mouse / IgG1

Reactivity

Virus

Applications

WB,Indirect ELISA

Conjugate

Unconjugated

CloneNo.

1H5E6

Cat No : 67794-1-PBS

Print datasheet

Synonyms

S protein, SARS-CoV-2 Spike Glycoprotein, SARS-CoV-2 Spike Glycoprotein (944-1214 aa), spike, spike protein



产品信息

67794-1-PBS targets SARS-CoV-2 S protein (944-1214 aa) in WB, Indirect ELISA applications and shows reactivity with Virus samples.

Tested Applications WB,Indirect ELISA Application Description
Tested Reactivity Virus
Immunogen SARS-CoV-2 S protein (944-1214 aa) fusion protein Ag30682 种属同源性预测
Host / Isotype Mouse / IgG1
Class Monoclonal
Type Antibody
Full Name SARS-CoV-2 Spike Protein
Synonyms S protein, SARS-CoV-2 Spike Glycoprotein, SARS-CoV-2 Spike Glycoprotein (944-1214 aa), spike, spike protein
Calculated Molecular Weight 141 kDa
GenBank Accession NumberNC_045512
Gene Symbol COVID-19 S Protein
Gene ID (NCBI) 43740568
Conjugate Unconjugated
Form Liquid
Purification MethodProtein A purification
Storage Buffer PBS Only
Storage ConditionsStore at -80°C.

背景介绍

Coronaviruses (CoVs) infect human and animals and cause varieties of diseases, including respiratory, enteric, renal, and neurological diseases. CoV uses its spike protein to recognize ACE2 as its receptors and mediate membrane fusion and virus entry into host cells(PMID: 32221306). Each monomer of trimeric S protein is about 180 kDa, and contains two subunits, S1 and S2,S1 recognizes and binds to host receptors, and subsequent conformational changes in S2 facilitate fusion between the viral envelope and the host cell membrane(PMID: 19198616). Although the amino acid sequences of the S-glycoprotein were found to be different between the various HCoV, the structures showed high similarity, but the best 3D structural overlap shared by SARS-CoV and SARS-CoV-2, consistent with the shared ACE2 predicted receptor (PMID: 32522207). The spike protein of CoVs can be a target for vaccine and therapeutic development (PMID: 19198616).